Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2024 16h19 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Joins the Russell 3000® Index
01 juil. 2024 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 juin 2024 16h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
15 mai 2024 07h52 HE
|
Solid Biosciences Inc.
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 — —...
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
07 mai 2024 07h00 HE
|
Solid Biosciences Inc.
— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — ...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2024 16h05 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 avr. 2024 16h05 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
01 avr. 2024 07h45 HE
|
Solid Biosciences Inc.
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass.,...
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
27 mars 2024 07h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
13 mars 2024 07h44 HE
|
Solid Biosciences Inc.
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into...